Retatrutide vs. Mounjaro: Two Drugs, One Company, Different Targets

An Unusual Portfolio Question

Eli Lilly is in a position few drug companies have been in: developing two different incretin-based therapies for overlapping uses in obesity and type 2 diabetes. Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity) is a dual GIP/GLP-1 receptor agonist already on the market. Retatrutide (LY3437943) is a triple GIP/GLP-1/glucagon receptor agonist still in Phase 3 development. To see how the two molecules differ, and how Lilly might position them, you have to look at their pharmacology, their clinical data and the wider market.

Dual vs. Triple Agonism

Tirzepatide activates two receptors: GIP and GLP-1. This dual mechanism produced record weight loss in the SURMOUNT trials, with mean reductions of up to 22.5% at 72 weeks in adults with obesity.

Retatrutide adds a third target: the glucagon receptor. Preclinical work published by Coskun et al. showed that in animal models this triple agonist approach produced more weight loss and greater metabolic improvement than dual agonism alone. The glucagon component is thought to raise energy expenditure mainly by burning fat in the liver and increasing heat production. That is a different contribution from appetite suppression and better insulin sensitivity.

In Phase 2 human data, retatrutide at the 12 mg dose showed 24.2% mean body weight loss at 48 weeks. Phase 3 has since confirmed and beaten this: TRIUMPH-4 (December 2025) showed 28.7% mean weight loss at 12 mg and 26.4% at 9 mg over 68 weeks in 445 participants with obesity and knee osteoarthritis, compared to 2.1% on placebo. This Phase 3 result surpasses tirzepatide’s 22.5% at 72 weeks in SURMOUNT-1, now with more comparable treatment durations.

Different Development Timelines

Tirzepatide is years ahead. It received FDA approval for type 2 diabetes in 2022 and for chronic weight management in 2023. Its safety and efficacy are backed by extensive Phase 3 data across many patient groups, including those with heart failure, obstructive sleep apnea, and type 2 diabetes.

Retatrutide is currently in Phase 3 trials, with its pivotal readouts reported between December 2025 (TRIUMPH-4) and October 2026 (TRANSCEND-T2D-2). Eli Lilly says it plans to file for approval no later than the first quarter of 2027; by our estimate, an FDA decision could come in late 2027 with priority review or around the first quarter of 2028 with standard review, roughly five years behind tirzepatide’s initial approvals. On October 2, 2026 the FDA ruled that retatrutide is a drug, not a biologic, so the application must be a New Drug Application (NDA); Lilly is contesting the FDA ruling in court and has not said which pathway it will use.

Potential Clinical Differentiation

If both drugs end up on the market for obesity, how might they differ in use? There are several possibilities:

• Efficacy magnitude: Phase 3 data point to greater weight loss than tirzepatide in cross-trial comparison (28.7% in TRIUMPH-4 and 28.3% in TRIUMPH-1, vs. 22.5% in SURMOUNT-1); the head-to-head TRIUMPH-5 trial is still running. For patients with severe obesity (BMI > 40), or those who have not reached their target weight on existing therapies, this stronger option could fill a clinical gap.
• Metabolic effects: The glucagon receptor component may bring distinct benefits for fatty liver and lipid metabolism. Early data suggest retatrutide cuts liver fat significantly, which could make it a good fit for patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
• Tolerability profile: TRIUMPH-4 gave the first large-scale picture. Gastrointestinal events were the same kind as with tirzepatide but more frequent: nausea 43.2%, diarrhea 33.1% and vomiting 20.9% at 12 mg, against 28%, 23% and 13% for tirzepatide 15 mg in the Zepbound label. A notable new finding is dysesthesia (abnormal skin sensation), which occurred in 20.9% of the 12 mg group versus 0.7% on placebo, a signal not seen with tirzepatide. Discontinuation rates were 18.2% at 12 mg. The later trials reported lower dysesthesia rates at 12 mg (12.5% in TRIUMPH-1, 7.3% in TRIUMPH-2, 6.4% in TRIUMPH-3); whether these tolerability differences matter in practice is not yet known.

Portfolio Strategy

Commercially, having two products may not be as redundant as it looks. The obesity drug market is expected to be big enough for several drugs, and patients may respond differently to dual and triple agonism. Two products also spread development risk: if one molecule runs into an unexpected safety signal, the other keeps the franchise going.

Each could also be aimed at different uses. Tirzepatide may become the standard first incretin therapy, while retatrutide could be aimed at patients who need more intensive treatment, or at specific conditions where the glucagon component adds benefit.

Looking Ahead

TRIUMPH-4 makes the relationship between tirzepatide and retatrutide in Lilly’s pipeline clearer. The Phase 3 data confirm that triple agonism produces meaningfully more weight loss than dual agonism, which supports the clinical value of targeting the glucagon receptor. With a filing planned no later than Q1 2027, Lilly will soon have to decide how to position the two. The likely answer is tirzepatide as the standard first-line therapy and retatrutide as the more intensive option for patients who need more weight loss or who have specific conditions like osteoarthritis or MASLD.